pharma · Weight management · Short Bowel Syndrome
Zealand Pharma
Zealand Pharma A/S
Zealand Pharma clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydmarken 11, Søborg (Copenhagen), 2860, DK
- Founded
- 1998
- Employees
- 596
- Programs
- 18
- Drugs
- 20
- Patents
- 0
Zealand Pharma projects
7 ClinicalTrials.gov programs sponsored by Zealand Pharma.
Zealand Pharma has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Dasiglucagon 4 mg/ml
Zealand Pharma A/S
Children with congenital hyperinsulinism
1 trial -
Early activity and mobilisation
Zealand Pharma A/S
Critically Ill, Mechanically Ventilated
1 trial -
Glepaglutide 20.0 mg/mL
Zealand Pharma A/S
Short bowel syndrome
1 trial -
Glepaglutide 20.0 mg/mL
Zealand Pharma A/S
Short Bowel Syndrome
1 trial -
Glepaglutide 20.0 mg/mL, Glepaglutide Placebo
Zealand Pharma A/S
Short Bowel Syndrome
1 trial -
TARGET protocol EN 1.5 kcal/mL
Zealand Pharma A/S
Critical Illness
1 trial -
ZP1848-23029
Zealand Pharma A/S
Short Bowel Syndrome
1 trial
Frequently asked questions
How many clinical projects does Zealand Pharma have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.